Sanofi's tolebrutinib received a surprise endorsement from European regulators for progressive multiple sclerosis despite the FDA's December rejection, while Regeneron closed the Trump administration's ambitious 17-deal drug pricing initiative by offering its new hearing-loss therapy for free. Separately, the FDA issued complete response letters to both AbbVie's botulinum toxin candidate and Grace Therapeutics on manufacturing grounds.
Top Stories
Sanofi's Tolebrutinib Gains European Backing for MS Despite U.S. Rejection
The European Medicines Agency's CHMP recommended approval of Sanofi's tolebrutinib (Cenrifki) for non-relapsing secondary progressive multiple sclerosis, according to the EMA, positioning the BTK inhibitor for its first regulatory approval just months after the FDA issued a complete response letter in December 2025 citing safety concerns. BioPharma Dive and Endpoints News both reported the divergence highlights the transatlantic regulatory split on benefit-risk assessment for neurodegenerative diseases. This signals Europe's willingness to approve therapies for high-unmet-need populations where U.S. regulators remain cautious on safety profiles.
Regeneron Completes Trump Drug Pricing Deals, Will Offer Hearing-Loss Therapy for Free
Regeneron closed the Trump administration's series of 17 drug pricing agreements by committing to provide its new hearing-loss therapy at no cost, CNBC reported, with STAT noting the company joins a growing roster of major drugmakers making pricing concessions under White House pressure. The move suggests the administration's public deal-making strategy has successfully extracted industry commitments, though the long-term sustainability and coverage mechanics of such agreements remain unclear.
FDA Issues Manufacturing-Related CRLs to AbbVie and Grace Therapeutics
The FDA rejected AbbVie's trenibotulinumtoxinE, a prospective successor to Botox for aesthetic indications, alongside a Grace Therapeutics product, both on manufacturing-related grounds according to Fierce Pharma. The rejections add to a recent pattern of manufacturing-focused complete response letters that have delayed multiple high-profile product launches. Worth watching because AbbVie's franchise transition strategy now faces timing uncertainty as Botox patent cliffs approach.
EMA Recommends Five New Medicines Including Novartis Gene Therapy
The European regulator's CHMP recommended five medicines for approval at its April 2026 meeting, including Novartis' onasemnogene abeparvovec (Itvisma) for 5q spinal muscular atrophy, according to the EMA. The batch of recommendations reflects continued regulatory progress for gene therapies in rare disease indications where traditional treatment options remain limited.
WHO Prequalifies Novartis Malaria Drug
The World Health Organization granted prequalification to a Novartis malaria treatment, Endpoints News reported, enabling broader access in endemic regions through procurement programs. This signals progress in expanding the antimalarial arsenal as resistance patterns evolve globally.
Merck Completes Pembrolizumab Adjuvant HCC Trial
Merck's Phase 3 KEYNOTE-937 trial evaluating pembrolizumab versus placebo as adjuvant therapy in hepatocellular carcinoma patients with complete radiological response after resection or ablation has reached completed status, according to ClinicalTrials.gov. The trial completion positions Merck to potentially expand Keytruda's label into the adjuvant liver cancer setting, though top-line results have not yet been disclosed.
Biogen Acquires China Rights to Felzartamab for Up to $850M
Biogen secured exclusive Greater China rights to TJ Biopharma's anti-CD38 antibody felzartamab for multiple myeloma in a deal worth up to $850 million, Pharmaceutical Technology reported, positioning the therapy to challenge Johnson & Johnson's Darzalex in the region. The move suggests Biogen is pursuing geographic arbitrage opportunities in oncology as it diversifies beyond neurology franchises.
Avalyn Pharma Files for $182M IPO
Avalyn Pharma filed for an initial public offering targeting approximately $182 million in net proceeds to advance its inhaled formulations of approved pulmonary fibrosis medicines, Endpoints News reported. Worth watching because inhaled reformulations represent a less risky development path than novel mechanisms, though differentiation and reimbursement remain key hurdles.
What to Watch
- Tolebrutinib U.S. Path — Sanofi will need to address FDA safety concerns and potentially conduct additional studies to secure U.S. approval, creating a 12-18 month European-only commercialization window.
- Trump Pricing Deal Mechanics — With all 17 agreements now closed, implementation details around patient access, provider reimbursement, and sustainability of free-drug commitments will determine policy impact.
- Manufacturing CRL Trend — The string of manufacturing-related rejections suggests heightened FDA scrutiny on CMC packages, particularly for complex biologics and injectables.
- China Oncology Competition — Biogen's felzartamab bet reflects increasing Western pharma interest in Chinese rights deals as local innovation accelerates and the market matures.
Market Snapshot
- BTK Inhibitor Market: The tolebrutinib approval in Europe validates the CNS-penetrant BTK class for progressive MS, potentially opening a multi-billion dollar opportunity as Roche, Merck KGaA, and others advance competing programs.
- Gene Therapy Momentum: Novartis' second European nod for onasemnogene abeparvovec underscores gene therapy's march toward routine regulatory acceptance in rare disease, with 8-10 new approvals expected in 2026.
- Specialty Pharma IPO Window: Avalyn's $182M filing tests investor appetite for low-risk reformulation plays amid broader biotech market volatility, with respiratory franchises attracting premium valuations.